To embed, copy and paste the code into your website or blog:
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
G.D. Searle LLC et al. v. Lupin Pharmaceuticals, Inc. et al.
2:13-cv-00121; filed March 5, 2013 in the Eastern District of Virginia
• Plaintiffs: G.D. Searle LLC; Pfizer Asia Pacific PTE, LTD.;
• Defendants: Lupin Pharmaceuticals, Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Watson Laboratories, Inc.; Apotex Inc.; Apotex Corp.
Infringement of U.S. Patent No. RE44,048 ("4-[5-(4-Methylphenyl)-3-(Trifluoromethyl)-1H-Pyrazol-1-yl]Benzenesulfonamide for the Treatment of Inflammation or an Inflammation-Associated Disorder," reissued march 5, 2013) in conjunction with defendants' filing of an ANDA to manufacture a generic version of Pfizer's Celebrex® (celecoxib, used to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea). View the complaint here.
AbbVie Inc. et al. v. The Kennedy Trust Rheumatology Research
1:13-cv-01358; filed February 28, 2013 in the Southern District of New York
• Plaintiffs: AbbVie Inc.; AbbVie Biotechnology Limited
• Defendant: The Kennedy Trust Rheumatology Research
Declaratory judgment of invalidity of U.S. Patent Nos. 8,298,537 ("Concomitant Treatment of Rheumatoid Arthritis with Anti-TNF-a Antibodies and Methotrexate," issued October 30, 2012) and 8,383,120 (same title, issued February 26, 2013) in conjunction with Abbott's manufacture and sale of its Humira® (adalimumab, used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and plaque psoriasis). View the complaint here.
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© McDonnell Boehnen Hulbert & Berghoff LLP
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up to create your digest using LinkedIn*
Back to Top